IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors
A total of 343 brain tumors were studied for IDH1 and IDH2 mutations by direct sequencing and for protein expression by immunohistochemistry with mIDH1 R132H antibody. Of these, 287 were gliomas (17 pilocytic astrocytomas, 13 grade II and 5 grade III astrocytomas, 167 primary (pGBMs) and 19 secondar...
Saved in:
Published in | Journal of neuro-oncology Vol. 105; no. 2; pp. 345 - 357 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Boston
Springer US
01.11.2011
Springer Nature B.V |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | A total of 343 brain tumors were studied for
IDH1
and
IDH2
mutations by direct sequencing and for protein expression by immunohistochemistry with mIDH1
R132H
antibody. Of these, 287 were gliomas (17 pilocytic astrocytomas, 13 grade II and 5 grade III astrocytomas, 167 primary (pGBMs) and 19 secondary (sGBMs) glioblastomas, 36 grade II and 26 grade III oligodendrogliomas and 4 grade II–III oligoastrocytomas). In gliomas,
IDH1
mutations at codon R132 were identified in 22.3%, of which 93.7% were c.395G>A (p.R132H). Mutations were more frequent in oligodendrogliomas (53.2%) than in astrocytic tumors (22.8%) and in sGBMs (84.2%) upon pGBMs (1.8%). There was a statistically significant correlation between mIDH1
R132H
antibody immunostaining and the relevant mutation c.395G>A (p.R132H) (
P
= 0.0001). No mutations were identified in non-glial tumors which were also negative to immunohistochemistry, with the exception of one PNET. A c.515G>T (p.R172M) mutation of the
IDH2
gene was only identified in a grade II oligodendroglioma patient which was wild-type for
IDH1
. A direct correlation with
MGMT
promoter hypermethylation status and an inverse correlation with
EGFR
amplification was found, whereas the relationships with 1p/19q co-deletion and
TP53
mutations only showed a trend toward correlation. In all gliomas, a positive correlation was found between
IDH1
mutations and a young age (
P
= 0.0001). In contrast, a correlation with overall survival could only be obtained in low-grade gliomas. Immunohistochemistry appeared to be useful in differential diagnoses, especially toward non-tumor pathologic nervous tissue, and in recognizing infiltrating glioma cells. The mIDH1
R132H
antibody positivity was complementary with Cyclin D1 expression. |
---|---|
AbstractList | A total of 343 brain tumors were studied for IDH1 and IDH2 mutations by direct sequencing and for protein expression by immunohistochemistry with mIDH1 super(R132H) antibody. Of these, 287 were gliomas (17 pilocytic astrocytomas, 13 grade II and 5 grade III astrocytomas, 167 primary (pGBMs) and 19 secondary (sGBMs) glioblastomas, 36 grade II and 26 grade III oligodendrogliomas and 4 grade II-III oligoastrocytomas). In gliomas, IDH1 mutations at codon R132 were identified in 22.3%, of which 93.7% were c.395G>A (p.R132H). Mutations were more frequent in oligodendrogliomas (53.2%) than in astrocytic tumors (22.8%) and in sGBMs (84.2%) upon pGBMs (1.8%). There was a statistically significant correlation between mIDH1 super(R132H) antibody immunostaining and the relevant mutation c.395G>A (p.R132H) (P = 0.0001). No mutations were identified in non-glial tumors which were also negative to immunohistochemistry, with the exception of one PNET. A c.515G>T (p.R172M) mutation of the IDH2 gene was only identified in a grade II oligodendroglioma patient which was wild-type for IDH1. A direct correlation with MGMT promoter hypermethylation status and an inverse correlation with EGFR amplification was found, whereas the relationships with 1p/19q co-deletion and TP53 mutations only showed a trend toward correlation. In all gliomas, a positive correlation was found between IDH1 mutations and a young age (P = 0.0001). In contrast, a correlation with overall survival could only be obtained in low-grade gliomas. Immunohistochemistry appeared to be useful in differential diagnoses, especially toward non-tumor pathologic nervous tissue, and in recognizing infiltrating glioma cells. The mIDH1 super(R132H) antibody positivity was complementary with Cyclin D1 expression. A total of 343 brain tumors were studied for IDH1 and IDH2 mutations by direct sequencing and for protein expression by immunohistochemistry with mIDH1^sup R132H^ antibody. Of these, 287 were gliomas (17 pilocytic astrocytomas, 13 grade II and 5 grade III astrocytomas, 167 primary (pGBMs) and 19 secondary (sGBMs) glioblastomas, 36 grade II and 26 grade III oligodendrogliomas and 4 grade II-III oligoastrocytomas). In gliomas, IDH1 mutations at codon R132 were identified in 22.3%, of which 93.7% were c.395G>A (p.R132H). Mutations were more frequent in oligodendrogliomas (53.2%) than in astrocytic tumors (22.8%) and in sGBMs (84.2%) upon pGBMs (1.8%). There was a statistically significant correlation between mIDH1^sup R132H^ antibody immunostaining and the relevant mutation c.395G>A (p.R132H) (P = 0.0001). No mutations were identified in non-glial tumors which were also negative to immunohistochemistry, with the exception of one PNET. A c.515G>T (p.R172M) mutation of the IDH2 gene was only identified in a grade II oligodendroglioma patient which was wild-type for IDH1. A direct correlation with MGMT promoter hypermethylation status and an inverse correlation with EGFR amplification was found, whereas the relationships with 1p/19q co-deletion and TP53 mutations only showed a trend toward correlation. In all gliomas, a positive correlation was found between IDH1 mutations and a young age (P = 0.0001). In contrast, a correlation with overall survival could only be obtained in low-grade gliomas. Immunohistochemistry appeared to be useful in differential diagnoses, especially toward non-tumor pathologic nervous tissue, and in recognizing infiltrating glioma cells. The mIDH1^sup R132H^ antibody positivity was complementary with Cyclin D1 expression.[PUBLICATION ABSTRACT] A total of 343 brain tumors were studied for IDH1 and IDH2 mutations by direct sequencing and for protein expression by immunohistochemistry with mIDH1 R132H antibody. Of these, 287 were gliomas (17 pilocytic astrocytomas, 13 grade II and 5 grade III astrocytomas, 167 primary (pGBMs) and 19 secondary (sGBMs) glioblastomas, 36 grade II and 26 grade III oligodendrogliomas and 4 grade II–III oligoastrocytomas). In gliomas, IDH1 mutations at codon R132 were identified in 22.3%, of which 93.7% were c.395G>A (p.R132H). Mutations were more frequent in oligodendrogliomas (53.2%) than in astrocytic tumors (22.8%) and in sGBMs (84.2%) upon pGBMs (1.8%). There was a statistically significant correlation between mIDH1 R132H antibody immunostaining and the relevant mutation c.395G>A (p.R132H) ( P = 0.0001). No mutations were identified in non-glial tumors which were also negative to immunohistochemistry, with the exception of one PNET. A c.515G>T (p.R172M) mutation of the IDH2 gene was only identified in a grade II oligodendroglioma patient which was wild-type for IDH1 . A direct correlation with MGMT promoter hypermethylation status and an inverse correlation with EGFR amplification was found, whereas the relationships with 1p/19q co-deletion and TP53 mutations only showed a trend toward correlation. In all gliomas, a positive correlation was found between IDH1 mutations and a young age ( P = 0.0001). In contrast, a correlation with overall survival could only be obtained in low-grade gliomas. Immunohistochemistry appeared to be useful in differential diagnoses, especially toward non-tumor pathologic nervous tissue, and in recognizing infiltrating glioma cells. The mIDH1 R132H antibody positivity was complementary with Cyclin D1 expression. A total of 343 brain tumors were studied for IDH1 and IDH2 mutations by direct sequencing and for protein expression by immunohistochemistry with mIDH1(R132H) antibody. Of these, 287 were gliomas (17 pilocytic astrocytomas, 13 grade II and 5 grade III astrocytomas, 167 primary (pGBMs) and 19 secondary (sGBMs) glioblastomas, 36 grade II and 26 grade III oligodendrogliomas and 4 grade II-III oligoastrocytomas). In gliomas, IDH1 mutations at codon R132 were identified in 22.3%, of which 93.7% were c.395G>A (p.R132H). Mutations were more frequent in oligodendrogliomas (53.2%) than in astrocytic tumors (22.8%) and in sGBMs (84.2%) upon pGBMs (1.8%). There was a statistically significant correlation between mIDH1(R132H) antibody immunostaining and the relevant mutation c.395G>A (p.R132H) (P = 0.0001). No mutations were identified in non-glial tumors which were also negative to immunohistochemistry, with the exception of one PNET. A c.515G>T (p.R172M) mutation of the IDH2 gene was only identified in a grade II oligodendroglioma patient which was wild-type for IDH1. A direct correlation with MGMT promoter hypermethylation status and an inverse correlation with EGFR amplification was found, whereas the relationships with 1p/19q co-deletion and TP53 mutations only showed a trend toward correlation. In all gliomas, a positive correlation was found between IDH1 mutations and a young age (P = 0.0001). In contrast, a correlation with overall survival could only be obtained in low-grade gliomas. Immunohistochemistry appeared to be useful in differential diagnoses, especially toward non-tumor pathologic nervous tissue, and in recognizing infiltrating glioma cells. The mIDH1(R132H) antibody positivity was complementary with Cyclin D1 expression. |
Author | Mellai, Marta Monzeglio, Oriana Valente, Guido Piazzi, Angela Schiffer, Davide Cassoni, Paola Caldera, Valentina |
Author_xml | – sequence: 1 givenname: Marta surname: Mellai fullname: Mellai, Marta organization: Neuro-Bio-Oncology Center, Policlinico di Monza Foundation, University of Turin – sequence: 2 givenname: Angela surname: Piazzi fullname: Piazzi, Angela organization: Department of Medical Sciences, University of Piemonte Orientale – sequence: 3 givenname: Valentina surname: Caldera fullname: Caldera, Valentina organization: Neuro-Bio-Oncology Center, Policlinico di Monza Foundation, University of Turin – sequence: 4 givenname: Oriana surname: Monzeglio fullname: Monzeglio, Oriana organization: Neuro-Bio-Oncology Center, Policlinico di Monza Foundation, University of Turin – sequence: 5 givenname: Paola surname: Cassoni fullname: Cassoni, Paola organization: Department of Biomedical Sciences and Human Oncology, University of Turin – sequence: 6 givenname: Guido surname: Valente fullname: Valente, Guido organization: Department of Clinical and Experimental Medicine, University of Piemonte Orientale – sequence: 7 givenname: Davide surname: Schiffer fullname: Schiffer, Davide email: davide.schiffer@unito.it organization: Neuro-Bio-Oncology Center, Policlinico di Monza Foundation, University of Turin |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/21643842$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkUtr3DAURkVJaGaS_oBuiuimmzi9V7IleVnSvCCQTQohGyHLcuNhLE0lezH_Ppo4DyiErK4e535X4izJng_eEfIV4QQB5M-ECAIKQCygqkXBP5EFVpIXkku-RxaAQhZVXd4dkGVKKwAoJcfP5IChKLkq2YLcX_2-RGp8S_OC0WEazdgHn45pPwyTDw99GoN9cEOucfsEmpSC7WeM9p4amlzsXaKho000-WSchhDTEdnvzDq5L8_1kPw5P7s9vSyuby6uTn9dF7YUaiza0hng4GzZcGUMKMVFy2VjTQfABFMib0BYkDV32FrOW8YaZFUHEpyy_JD8mHM3MfybXBp1fqx167XxLkxJ14hYVVWpPiYBBEeBdSa__0euwhR9_oZWdY11hXIH4QzZGFKKrtOb2A8mbjWC3gnSsyCdBemdIM1zz7fn4KkZXPva8WIkA2wGUr7yf118m_x-6iNAFZs3 |
CitedBy_id | crossref_primary_10_3390_cancers15072183 crossref_primary_10_3390_brainsci11010116 crossref_primary_10_1007_s11060_013_1186_3 crossref_primary_10_4132_KoreanJPathol_2013_47_6_541 crossref_primary_10_3892_ol_2017_6243 crossref_primary_10_1093_neuonc_nos317 crossref_primary_10_18632_oncotarget_21482 crossref_primary_10_1089_omi_2017_0087 crossref_primary_10_1016_j_bbrc_2018_04_011 crossref_primary_10_1111_his_12252 crossref_primary_10_1155_2013_756302 crossref_primary_10_2217_cns_2017_0019 crossref_primary_10_1007_s10014_014_0202_4 crossref_primary_10_7705_biomedica_v38i0_3708 crossref_primary_10_1093_neuonc_not087 crossref_primary_10_1186_s12885_015_1125_0 crossref_primary_10_1002_cjp2_134 crossref_primary_10_1111_neup_12196 crossref_primary_10_1111_bpa_12309 crossref_primary_10_4103_glioma_glioma_11_20 crossref_primary_10_1007_s12254_012_0030_3 crossref_primary_10_1007_s12031_012_9868_4 crossref_primary_10_3892_ol_2017_7386 crossref_primary_10_1002_jnr_23456 crossref_primary_10_5858_arpa_2021_0295_CP crossref_primary_10_1038_s41379_018_0147_y crossref_primary_10_1155_2012_273947 crossref_primary_10_1186_s13045_014_0076_2 crossref_primary_10_1007_s13402_017_0362_4 crossref_primary_10_1097_PPO_0000000000000020 crossref_primary_10_1002_gcc_20927 crossref_primary_10_1093_neuonc_not015 crossref_primary_10_4103_jcrt_jcrt_102_21 crossref_primary_10_1093_jnci_djs357 crossref_primary_10_1007_s11060_014_1407_4 crossref_primary_10_1007_s11060_016_2157_2 crossref_primary_10_1111_bpa_12018 crossref_primary_10_1007_s11060_015_2048_y crossref_primary_10_1007_s11060_016_2296_5 crossref_primary_10_4236_scd_2012_23017 crossref_primary_10_1007_s11060_013_1107_5 crossref_primary_10_4132_jptm_2019_07_15 crossref_primary_10_1093_neuonc_nor202 crossref_primary_10_1097_NEN_0000000000000213 crossref_primary_10_3390_cancers13215362 crossref_primary_10_1007_s11060_011_0787_y crossref_primary_10_1097_PAI_0000000000000342 crossref_primary_10_1158_1535_7163_MCT_18_0533 crossref_primary_10_1016_j_ibror_2018_11_005 crossref_primary_10_1093_neuonc_nou351 crossref_primary_10_1002_brb3_718 crossref_primary_10_1155_2015_413897 crossref_primary_10_1007_s11910_017_0722_5 crossref_primary_10_3390_cells9061538 crossref_primary_10_1016_j_mric_2016_07_001 crossref_primary_10_18632_oncotarget_3611 crossref_primary_10_3390_biom10050727 crossref_primary_10_1259_bjr_20190324 crossref_primary_10_1097_PCR_0b013e3182a9ab82 crossref_primary_10_1097_PAP_0000000000000048 crossref_primary_10_1007_s11060_012_0839_y crossref_primary_10_1097_PAP_0000000000000049 crossref_primary_10_1002_jcb_27966 crossref_primary_10_1016_j_mam_2015_05_002 crossref_primary_10_1007_s10143_017_0903_3 crossref_primary_10_12688_f1000research_18721_1 crossref_primary_10_12688_f1000research_18721_2 |
Cites_doi | 10.1056/NEJMoa0808710 10.1111/j.1750-3639.2010.00454.x 10.1007/s004010050776 10.1212/WNL.0b013e3181e1cf3a 10.1016/j.molmed.2010.07.002 10.1212/WNL.0b013e3181f96282 10.1007/s00401-009-0595-z 10.1097/PAS.0b013e3181e7740d 10.1097/NEN.0b013e3181c391be 10.1016/j.ccr.2010.11.015 10.1126/science.1164382 10.1158/1078-0432.CCR-07-0573 10.1200/JCO.2009.23.0805 10.1002/humu.20937 10.1038/ng.223 10.1016/j.ccr.2010.12.014 10.1007/s00401-008-0455-2 10.1002/humu.21201 10.1038/nature08617 10.1158/1078-0432.CCR-09-2902 10.1007/s00401-009-0550-z 10.1016/j.mehy.2007.04.024 10.1007/s11060-009-9855-y 10.1046/j.1440-1789.2001.00389.x 10.2353/ajpath.2009.080958 10.2353/ajpath.2010.100680 10.1212/WNL.0b013e3181c34ace 10.1215/15228517-2009-025 10.1158/1078-0432.CCR-09-0715 10.1002/ijc.24379 10.1111/j.1750-3639.2009.00352.x 10.1007/s00401-010-0781-z 10.1007/BF00295665 10.1007/s00401-009-0561-9 10.1016/j.bbrc.2010.10.038 10.1111/j.1349-7006.2009.01270.x 10.1007/s00401-009-0528-x 10.1007/s00401-010-0777-8 10.1200/JCO.2009.21.9832 10.1007/s00401-009-0632-y 10.1007/s10014-010-0016-y 10.1002/pbc.22697 10.1016/S0021-9258(18)43581-8 10.1002/ijc.25448 |
ContentType | Journal Article |
Copyright | Springer Science+Business Media, LLC. 2011 |
Copyright_xml | – notice: Springer Science+Business Media, LLC. 2011 |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7TK 7X7 7XB 88E 8AO 8C1 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. M0S M1P PQEST PQQKQ PQUKI 7X8 |
DOI | 10.1007/s11060-011-0596-3 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Neurosciences Abstracts ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection ProQuest Public Health Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central AUTh Library subscriptions: ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef ProQuest Public Health ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Pharma Collection Neurosciences Abstracts ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest One Academic ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | Neurosciences Abstracts ProQuest Public Health MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: 7X7 name: ProQuest Health & Medical Collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1573-7373 |
EndPage | 357 |
ExternalDocumentID | 2489735091 10_1007_s11060_011_0596_3 21643842 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- -53 -5E -5G -BR -EM -Y2 -~C .86 .GJ .VR 06C 06D 0R~ 0VY 199 1N0 1SB 2.D 203 28- 29L 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 3V. 4.4 406 408 409 40D 40E 53G 5GY 5QI 5VS 67Z 6NX 78A 7X7 88E 8AO 8C1 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AABYN AAFGU AAHNG AAIAL AAJKR AAKSU AANXM AANZL AARHV AARTL AATNV AATVU AAUYE AAWCG AAYFA AAYIU AAYQN AAYTO ABBBX ABBXA ABDZT ABECU ABFGW ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKAS ABKCH ABKTR ABMNI ABMQK ABNWP ABPLI ABQBU ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABUWZ ABWNU ABXPI ACBMV ACBRV ACBXY ACBYP ACGFS ACHSB ACHVE ACHXU ACIGE ACIPQ ACKNC ACMDZ ACMLO ACOKC ACOMO ACPRK ACTTH ACUDM ACVWB ACWMK ADBBV ADHHG ADHIR ADIMF ADINQ ADJJI ADKNI ADKPE ADMDM ADOXG ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEEQQ AEFIE AEFTE AEGAL AEGNC AEJHL AEJRE AEKMD AENEX AEOHA AEPYU AESKC AESTI AETLH AEVLU AEVTX AEXYK AFAFS AFEXP AFJLC AFKRA AFLOW AFNRJ AFQWF AFWTZ AFZKB AGAYW AGDGC AGGBP AGGDS AGJBK AGKHE AGMZJ AGQMX AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIIXL AILAN AIMYW AITGF AJBLW AJDOV AJRNO AJZVZ AKMHD AKQUC ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBWZM BDATZ BENPR BGNMA BPHCQ BVXVI CAG CCPQU COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP EBD EBLON EBS EIOEI EJD EMOBN EN4 ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GRRUI GXS HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IKXTQ IMOTQ IWAJR IXC IXD IXE IZIGR IZQ I~X I~Y I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH LAK LLZTM M1P M4Y MA- N2Q N9A NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM OVD P19 P2P P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RNI RNS ROL RPX RRX RSV RZC RZE RZK S16 S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TEORI TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UNUBA UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 YLTOR Z45 Z7U Z81 Z82 Z83 Z87 Z8O Z8U Z8V Z8W Z91 ZGI ZMTXR ZOVNA ZXP ~EX AACDK AAEOY AAJBT AASML ABAKF ACAOD ACDTI ACZOJ AEFQL AEMSY AFBBN AGQEE AGRTI AIGIU AJOOF ALIPV CGR CUY CVF ECM EIF NPM AAYXX CITATION H13 7TK 7XB 8FK K9. PQEST PQUKI 7X8 |
ID | FETCH-LOGICAL-c468t-d4ea030ec4b38aa08836d37bcaf002628637b06c0793e1dc33d22b125f070e8c3 |
IEDL.DBID | 8C1 |
ISSN | 0167-594X |
IngestDate | Fri Aug 16 04:19:08 EDT 2024 Sat Aug 17 01:44:30 EDT 2024 Fri Sep 13 06:23:21 EDT 2024 Thu Sep 12 17:12:22 EDT 2024 Sun Jul 28 07:00:26 EDT 2024 Sat Dec 16 12:04:45 EST 2023 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | Immunohistochemistry mutations and Brain tumors |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c468t-d4ea030ec4b38aa08836d37bcaf002628637b06c0793e1dc33d22b125f070e8c3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
PMID | 21643842 |
PQID | 899195179 |
PQPubID | 37423 |
PageCount | 13 |
ParticipantIDs | proquest_miscellaneous_911155548 proquest_miscellaneous_900631619 proquest_journals_899195179 crossref_primary_10_1007_s11060_011_0596_3 pubmed_primary_21643842 springer_journals_10_1007_s11060_011_0596_3 |
PublicationCentury | 2000 |
PublicationDate | 2011-11-01 |
PublicationDateYYYYMMDD | 2011-11-01 |
PublicationDate_xml | – month: 11 year: 2011 text: 2011-11-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Boston |
PublicationPlace_xml | – name: Boston – name: United States – name: New York |
PublicationTitle | Journal of neuro-oncology |
PublicationTitleAbbrev | J Neurooncol |
PublicationTitleAlternate | J Neurooncol |
PublicationYear | 2011 |
Publisher | Springer US Springer Nature B.V |
Publisher_xml | – name: Springer US – name: Springer Nature B.V |
References | Nobusawa, Watanabe, Kleihues (CR5) 2009; 15 von Deimling, Korshunov, Hartmann (CR17) 2011; 21 van den Bent, Dubbink, Marie (CR24) 2010; 16 Sonoda, Kumabe, Nakamura (CR9) 2009; 100 Schiffer (CR48) 2006 Balss, Meyer, Mueller (CR2) 2008; 116 Capper, Zentgraf, Balss (CR31) 2009; 118 Korshunov, Meyer, Capper (CR32) 2009; 118 Camelo-Piragua, Jansen, Ganguly (CR35) 2010; 119 Labussière, Idbaih, Wang (CR25) 2010; 74 Esteller, Hamilton, Burger (CR39) 1999; 59 Capper, Weissert, Balss (CR33) 2010; 20 Hartmann, Meyer, Balss (CR4) 2009; 118 Bosone, Cavalla, Chiadò-Piat (CR46) 2001; 21 Louis, Ohgaki, Wiestler (CR37) 2007 CR12 Yan, Parsons, Jin (CR3) 2009; 360 Zou, Zeng, Zhang, Zou, Cheng, Yao (CR15) 2010; 402 Capper, Sahm, Hartmann (CR34) 2010; 34 Metellus, Coulibaly, Colin (CR44) 2010; 120 Parsons, Jones, Zhang (CR1) 2008; 321 Watanabe, Nobusawa, Kleihues (CR7) 2009; 174 Watanabe, Vital, Nobusawa (CR19) 2009; 117 Narahara, Kimura, Kikkawa (CR20) 1985; 71 Xu, Yang, Liu (CR41) 2011; 19 Weller, Felsberg, Hartmann (CR26) 2009; 27 Kang, Kim, Oh (CR13) 2009; 125 Figueroa, Abdel-Wahab, Lu (CR42) 2010; 18 Cavalla, Dutto, Piva (CR45) 1998; 95 Dang, Jin, Su (CR14) 2010; 16 Houillier, Wang, Kaloshi (CR30) 2010; 75 Hartmann, Hentschel, Wick (CR43) 2010; 120 Holdhoff, Parsons, Diaz (CR16) 2009; 94 Bleeker, Lamba, Leenstra (CR11) 2009; 30 Mellai, Caldera, Annovazzi (CR38) 2009; 6 Dubbink, Taal, van Marion (CR29) 2009; 73 Kim, Nobusawa, Mittelbronn (CR36) 2010; 177 Diabira, Morandi (CR47) 2008; 70 Hartong, Dange, McGee (CR22) 2008; 40 Horbinski, Kofler, Kelly (CR8) 2009; 68 Ramachandran, Colman (CR21) 1980; 255 Toedt, Barbus, Wolter (CR28) 2010; 128 Weller, Berger, Hartmann (CR40) 2007; 13 Ichimura, Pearson, Kocialkowski (CR6) 2009; 11 Dang, White, Gross (CR23) 2009; 462 Sanson, Marie, Paris (CR27) 2009; 27 Gravendeel, Kloosterhof, Bralten (CR18) 2010; 31 Ikota, Nobusawa, Tanaka (CR10) 2011; 28 21251613 - Cancer Cell. 2011 Jan 18;19(1):17-30 19798509 - Acta Neuropathol. 2009 Nov;118(5):599-601 19755387 - Clin Cancer Res. 2009 Oct 1;15(19):6002-7 20427748 - Neurology. 2010 Jun 8;74(23):1886-90 10029064 - Cancer Res. 1999 Feb 15;59(4):793-7 19117336 - Hum Mutat. 2009 Jan;30(1):7-11 21088844 - Acta Neuropathol. 2010 Dec;120(6):707-18 19350208 - J Neurooncol. 2009 Sep;94(2):297 19656999 - Cancer Genomics Proteomics. 2009 Jul-Aug;6(4):219-27 18056167 - Clin Cancer Res. 2007 Dec 1;13(23):6933-7 19903171 - Brain Pathol. 2010 Jan;20(1):245-54 19935646 - Nature. 2009 Dec 10;462(7274):739-44 20077503 - Hum Mutat. 2010 Mar;31(3):E1186-99 19933982 - Neurology. 2009 Nov 24;73(21):1792-5 18772396 - Science. 2008 Sep 26;321(5897):1807-12 9498046 - Acta Neuropathol. 1998 Feb;95(2):131-5 21213123 - Brain Tumor Pathol. 2011 Apr;28(2):107-14 11666011 - Neuropathology. 2001 Sep;21(3):155-61 19543740 - Acta Neuropathol. 2009 Sep;118(3):401-5 21130701 - Cancer Cell. 2010 Dec 14;18(6):553-67 19765000 - Cancer Sci. 2009 Oct;100(10):1996-8 21075857 - Am J Pathol. 2010 Dec;177(6):2708-14 18806796 - Nat Genet. 2008 Oct;40(10):1230-4 19378339 - Int J Cancer. 2009 Jul 15;125(2):353-5 20692206 - Trends Mol Med. 2010 Sep;16(9):387-97 19805672 - J Clin Oncol. 2009 Dec 1;27(34):5743-50 21129061 - Brain Pathol. 2011 Jan;21(1):74-87 20160062 - Clin Cancer Res. 2010 Mar 1;16(5):1597-604 19340432 - Acta Neuropathol. 2009 Jun;117(6):653-6 20975057 - Neurology. 2010 Oct 26;75(17 ):1560-6 20946881 - Biochem Biophys Res Commun. 2010 Nov 12;402(2):378-83 19228619 - N Engl J Med. 2009 Feb 19;360(8):765-73 19246647 - Am J Pathol. 2009 Apr;174(4):1149-53 21080178 - Acta Neuropathol. 2010 Dec;120(6):719-29 19636000 - J Clin Oncol. 2009 Sep 1;27(25):4150-4 19915484 - J Neuropathol Exp Neurol. 2009 Dec;68(12):1319-25 3861566 - Hum Genet. 1985;71(1):37-40 19435942 - Neuro Oncol. 2009 Aug;11(4):341-7 18985363 - Acta Neuropathol. 2008 Dec;116(6):597-602 20044756 - Acta Neuropathol. 2010 Apr;119(4):509-11 17614215 - Med Hypotheses. 2008;70(1):96-104 7410398 - J Biol Chem. 1980 Sep 25;255(18):8859-64 20661018 - Am J Surg Pathol. 2010 Aug;34(8):1199-204 19554337 - Acta Neuropathol. 2009 Oct;118(4):469-74 21225914 - Pediatr Blood Cancer. 2011 Mar;56(3):379-83 20473936 - Int J Cancer. 2011 Mar 1;128(5):1095-103 T Watanabe (596_CR7) 2009; 174 C Horbinski (596_CR8) 2009; 68 M Sanson (596_CR27) 2009; 27 W Xu (596_CR41) 2011; 19 HJ Dubbink (596_CR29) 2009; 73 N Ramachandran (596_CR21) 1980; 255 M Mellai (596_CR38) 2009; 6 D Schiffer (596_CR48) 2006 LA Gravendeel (596_CR18) 2010; 31 L Dang (596_CR14) 2010; 16 H Yan (596_CR3) 2009; 360 MR Kang (596_CR13) 2009; 125 K Ichimura (596_CR6) 2009; 11 M Labussière (596_CR25) 2010; 74 P Metellus (596_CR44) 2010; 120 M Esteller (596_CR39) 1999; 59 K Narahara (596_CR20) 1985; 71 D Capper (596_CR33) 2010; 20 S Diabira (596_CR47) 2008; 70 I Bosone (596_CR46) 2001; 21 C Hartmann (596_CR4) 2009; 118 S Nobusawa (596_CR5) 2009; 15 MJ Bent van den (596_CR24) 2010; 16 DN Louis (596_CR37) 2007 D Capper (596_CR34) 2010; 34 D Capper (596_CR31) 2009; 118 DW Parsons (596_CR1) 2008; 321 Y Sonoda (596_CR9) 2009; 100 596_CR28 L Dang (596_CR23) 2009; 462 A Korshunov (596_CR32) 2009; 118 FE Bleeker (596_CR11) 2009; 30 DT Hartong (596_CR22) 2008; 40 S Camelo-Piragua (596_CR35) 2010; 119 C Houillier (596_CR30) 2010; 75 J Balss (596_CR2) 2008; 116 C Hartmann (596_CR43) 2010; 120 T Watanabe (596_CR19) 2009; 117 A Deimling von (596_CR17) 2011; 21 M Holdhoff (596_CR16) 2009; 94 P Cavalla (596_CR45) 1998; 95 596_CR10 596_CR12 M Weller (596_CR26) 2009; 27 YH Kim (596_CR36) 2010; 177 Y Zou (596_CR15) 2010; 402 M Weller (596_CR40) 2007; 13 ME Figueroa (596_CR42) 2010; 18 |
References_xml | – volume: 360 start-page: 765 year: 2009 end-page: 773 ident: CR3 article-title: IDH1 and IDH2 mutations in gliomas publication-title: N Engl J Med doi: 10.1056/NEJMoa0808710 contributor: fullname: Jin – volume: 21 start-page: 74 year: 2011 end-page: 87 ident: CR17 article-title: The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations publication-title: Brain Pathol doi: 10.1111/j.1750-3639.2010.00454.x contributor: fullname: Hartmann – volume: 95 start-page: 131 year: 1998 end-page: 135 ident: CR45 article-title: Cyclin D1 expression in gliomas publication-title: Acta Neuropathol doi: 10.1007/s004010050776 contributor: fullname: Piva – volume: 74 start-page: 1886 year: 2010 end-page: 1890 ident: CR25 article-title: All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2 publication-title: Neurology doi: 10.1212/WNL.0b013e3181e1cf3a contributor: fullname: Wang – volume: 16 start-page: 387 year: 2010 end-page: 397 ident: CR14 article-title: IDH mutations in glioma and acute myeloid leukemia publication-title: Trends Mol Med doi: 10.1016/j.molmed.2010.07.002 contributor: fullname: Su – volume: 255 start-page: 8859 year: 1980 end-page: 8864 ident: CR21 article-title: Chemical characterization of distinct subunits of pig heart DPN-specific isocitrate dehydrogenase publication-title: J Biol Chem contributor: fullname: Colman – volume: 75 start-page: 1560 year: 2010 end-page: 1566 ident: CR30 article-title: IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas publication-title: Neurology doi: 10.1212/WNL.0b013e3181f96282 contributor: fullname: Kaloshi – volume: 118 start-page: 599 year: 2009 end-page: 601 ident: CR31 article-title: Monoclonal antibody specific for R132H mutation publication-title: Acta Neuropathol doi: 10.1007/s00401-009-0595-z contributor: fullname: Balss – volume: 34 start-page: 1199 year: 2010 end-page: 1204 ident: CR34 article-title: Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes publication-title: Am J Surg Pathol doi: 10.1097/PAS.0b013e3181e7740d contributor: fullname: Hartmann – ident: CR12 – volume: 68 start-page: 1319 year: 2009 end-page: 1325 ident: CR8 article-title: Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues publication-title: J Neuropathol Exp Neurol doi: 10.1097/NEN.0b013e3181c391be contributor: fullname: Kelly – volume: 18 start-page: 553 year: 2010 end-page: 567 ident: CR42 article-title: Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation publication-title: Cancer Cell doi: 10.1016/j.ccr.2010.11.015 contributor: fullname: Lu – volume: 321 start-page: 1807 year: 2008 end-page: 1812 ident: CR1 article-title: An integrated genomic analysis of human glioblastoma multiforme publication-title: Science doi: 10.1126/science.1164382 contributor: fullname: Zhang – volume: 13 start-page: 6933 year: 2007 end-page: 6937 ident: CR40 article-title: Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker? publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-07-0573 contributor: fullname: Hartmann – volume: 27 start-page: 5743 year: 2009 end-page: 5750 ident: CR26 article-title: Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network publication-title: J Clin Oncol doi: 10.1200/JCO.2009.23.0805 contributor: fullname: Hartmann – volume: 30 start-page: 7 year: 2009 end-page: 11 ident: CR11 article-title: IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors publication-title: Hum Mutat doi: 10.1002/humu.20937 contributor: fullname: Leenstra – volume: 40 start-page: 1230 year: 2008 end-page: 1234 ident: CR22 article-title: Insights from retinitis pigmentosa into the roles of isocitrate dehydrogenases in the Krebs cycle publication-title: Nat Genet doi: 10.1038/ng.223 contributor: fullname: McGee – volume: 19 start-page: 17 year: 2011 end-page: 30 ident: CR41 article-title: Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases publication-title: Cancer Cell doi: 10.1016/j.ccr.2010.12.014 contributor: fullname: Liu – year: 2006 ident: CR48 publication-title: Brain tumor pathology: current diagnostic hotspots and pitfalls contributor: fullname: Schiffer – volume: 116 start-page: 597 year: 2008 end-page: 602 ident: CR2 article-title: Analysis of the IDH1 codon 132 mutation in brain tumors publication-title: Acta Neuropathol doi: 10.1007/s00401-008-0455-2 contributor: fullname: Mueller – volume: 31 start-page: E1186 year: 2010 end-page: E1199 ident: CR18 article-title: Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma publication-title: Hum Mutat doi: 10.1002/humu.21201 contributor: fullname: Bralten – volume: 462 start-page: 739 year: 2009 end-page: 744 ident: CR23 article-title: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate publication-title: Nature doi: 10.1038/nature08617 contributor: fullname: Gross – volume: 16 start-page: 1597 year: 2010 end-page: 1604 ident: CR24 article-title: IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-09-2902 contributor: fullname: Marie – volume: 118 start-page: 401 year: 2009 end-page: 405 ident: CR32 article-title: Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma publication-title: Acta Neuropathol doi: 10.1007/s00401-009-0550-z contributor: fullname: Capper – volume: 70 start-page: 96 year: 2008 end-page: 104 ident: CR47 article-title: Gliomagenesis and neural stem cells: key role of hypoxia and concept of tumor ‘neo-niche’ publication-title: Med Hypotheses doi: 10.1016/j.mehy.2007.04.024 contributor: fullname: Morandi – volume: 94 start-page: 297 year: 2009 ident: CR16 article-title: Mutations of IDH1 and IDH2 are not detected in brain metastases of colorectal cancer publication-title: J Neurooncol doi: 10.1007/s11060-009-9855-y contributor: fullname: Diaz – volume: 21 start-page: 155 year: 2001 end-page: 161 ident: CR46 article-title: Cyclin D1 expression in normal oligodendroglia and microglia cells: its use in the differential diagnosis of oligodendrogliomas publication-title: Neuropathology doi: 10.1046/j.1440-1789.2001.00389.x contributor: fullname: Chiadò-Piat – volume: 174 start-page: 1149 year: 2009 end-page: 1153 ident: CR7 article-title: IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas publication-title: Am J Pathol doi: 10.2353/ajpath.2009.080958 contributor: fullname: Kleihues – volume: 177 start-page: 2708 year: 2010 end-page: 2714 ident: CR36 article-title: Molecular classification of low-grade diffuse gliomas publication-title: Am J Pathol doi: 10.2353/ajpath.2010.100680 contributor: fullname: Mittelbronn – volume: 73 start-page: 1792 year: 2009 end-page: 1795 ident: CR29 article-title: IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide publication-title: Neurology doi: 10.1212/WNL.0b013e3181c34ace contributor: fullname: van Marion – volume: 6 start-page: 219 year: 2009 end-page: 227 ident: CR38 article-title: MGMT promoter hypermethylation in a series of 104 glioblastomas publication-title: Cancer Genomics Proteomics contributor: fullname: Annovazzi – volume: 11 start-page: 341 year: 2009 end-page: 347 ident: CR6 article-title: IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas publication-title: Neuro Oncol doi: 10.1215/15228517-2009-025 contributor: fullname: Kocialkowski – volume: 15 start-page: 6002 year: 2009 end-page: 6007 ident: CR5 article-title: IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-09-0715 contributor: fullname: Kleihues – volume: 128 start-page: 1095 year: 2010 end-page: 1103 ident: CR28 article-title: Molecular signatures classify astrocytic gliomas by IDH1 mutation status publication-title: Int J Cancer contributor: fullname: Wolter – volume: 125 start-page: 353 year: 2009 end-page: 355 ident: CR13 article-title: Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers publication-title: Int J Cancer doi: 10.1002/ijc.24379 contributor: fullname: Oh – volume: 20 start-page: 245 year: 2010 end-page: 254 ident: CR33 article-title: Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors publication-title: Brain Pathol doi: 10.1111/j.1750-3639.2009.00352.x contributor: fullname: Balss – volume: 120 start-page: 707 year: 2010 end-page: 718 ident: CR43 article-title: Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas publication-title: Acta Neuropathol doi: 10.1007/s00401-010-0781-z contributor: fullname: Wick – volume: 71 start-page: 37 year: 1985 end-page: 40 ident: CR20 article-title: Probable assignment of soluble isocitrate dehydrogenase (IDH1) to 2q33.3 publication-title: Hum Genet doi: 10.1007/BF00295665 contributor: fullname: Kikkawa – volume: 118 start-page: 469 year: 2009 end-page: 474 ident: CR4 article-title: Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas publication-title: Acta Neuropathol doi: 10.1007/s00401-009-0561-9 contributor: fullname: Balss – volume: 402 start-page: 378 year: 2010 end-page: 383 ident: CR15 article-title: IDH1 and IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia but rare in other types of hematological disorders publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2010.10.038 contributor: fullname: Yao – volume: 28 start-page: 107−114 year: 2011 ident: CR10 article-title: High-throughput immunohistochemical profiling of primary brain tumors and non-neoplastic systemic organs with a specific antibody against the mutant isocitrate dehydrogenase 1 R132H protein publication-title: Brain Tumor Pathol contributor: fullname: Tanaka – volume: 100 start-page: 1996 year: 2009 end-page: 1998 ident: CR9 article-title: Analysis of IDH1 and IDH2 mutations in Japanese glioma patients publication-title: Cancer Sci doi: 10.1111/j.1349-7006.2009.01270.x contributor: fullname: Nakamura – volume: 117 start-page: 653 year: 2009 end-page: 656 ident: CR19 article-title: Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome publication-title: Acta Neuropathol doi: 10.1007/s00401-009-0528-x contributor: fullname: Nobusawa – volume: 120 start-page: 719 year: 2010 end-page: 729 ident: CR44 article-title: Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis publication-title: Acta Neuropathol doi: 10.1007/s00401-010-0777-8 contributor: fullname: Colin – volume: 59 start-page: 793 year: 1999 end-page: 797 ident: CR39 article-title: Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia publication-title: Cancer Res contributor: fullname: Burger – volume: 27 start-page: 4150 year: 2009 end-page: 4154 ident: CR27 article-title: Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas publication-title: J Clin Oncol doi: 10.1200/JCO.2009.21.9832 contributor: fullname: Paris – volume: 119 start-page: 509 year: 2010 end-page: 511 ident: CR35 article-title: Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis publication-title: Acta Neuropathol doi: 10.1007/s00401-009-0632-y contributor: fullname: Ganguly – year: 2007 ident: CR37 publication-title: WHO classification of tumors of the central nervous systems contributor: fullname: Wiestler – volume: 11 start-page: 341 year: 2009 ident: 596_CR6 publication-title: Neuro Oncol doi: 10.1215/15228517-2009-025 contributor: fullname: K Ichimura – volume: 95 start-page: 131 year: 1998 ident: 596_CR45 publication-title: Acta Neuropathol doi: 10.1007/s004010050776 contributor: fullname: P Cavalla – volume: 125 start-page: 353 year: 2009 ident: 596_CR13 publication-title: Int J Cancer doi: 10.1002/ijc.24379 contributor: fullname: MR Kang – volume: 31 start-page: E1186 year: 2010 ident: 596_CR18 publication-title: Hum Mutat doi: 10.1002/humu.21201 contributor: fullname: LA Gravendeel – volume: 119 start-page: 509 year: 2010 ident: 596_CR35 publication-title: Acta Neuropathol doi: 10.1007/s00401-009-0632-y contributor: fullname: S Camelo-Piragua – volume: 59 start-page: 793 year: 1999 ident: 596_CR39 publication-title: Cancer Res contributor: fullname: M Esteller – volume: 177 start-page: 2708 year: 2010 ident: 596_CR36 publication-title: Am J Pathol doi: 10.2353/ajpath.2010.100680 contributor: fullname: YH Kim – volume: 13 start-page: 6933 year: 2007 ident: 596_CR40 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-07-0573 contributor: fullname: M Weller – volume: 70 start-page: 96 year: 2008 ident: 596_CR47 publication-title: Med Hypotheses doi: 10.1016/j.mehy.2007.04.024 contributor: fullname: S Diabira – volume: 27 start-page: 4150 year: 2009 ident: 596_CR27 publication-title: J Clin Oncol doi: 10.1200/JCO.2009.21.9832 contributor: fullname: M Sanson – volume: 402 start-page: 378 year: 2010 ident: 596_CR15 publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2010.10.038 contributor: fullname: Y Zou – ident: 596_CR10 doi: 10.1007/s10014-010-0016-y – volume: 20 start-page: 245 year: 2010 ident: 596_CR33 publication-title: Brain Pathol doi: 10.1111/j.1750-3639.2009.00352.x contributor: fullname: D Capper – ident: 596_CR12 doi: 10.1002/pbc.22697 – volume: 100 start-page: 1996 year: 2009 ident: 596_CR9 publication-title: Cancer Sci doi: 10.1111/j.1349-7006.2009.01270.x contributor: fullname: Y Sonoda – volume: 34 start-page: 1199 year: 2010 ident: 596_CR34 publication-title: Am J Surg Pathol doi: 10.1097/PAS.0b013e3181e7740d contributor: fullname: D Capper – volume: 120 start-page: 719 year: 2010 ident: 596_CR44 publication-title: Acta Neuropathol doi: 10.1007/s00401-010-0777-8 contributor: fullname: P Metellus – volume: 255 start-page: 8859 year: 1980 ident: 596_CR21 publication-title: J Biol Chem doi: 10.1016/S0021-9258(18)43581-8 contributor: fullname: N Ramachandran – volume: 21 start-page: 155 year: 2001 ident: 596_CR46 publication-title: Neuropathology doi: 10.1046/j.1440-1789.2001.00389.x contributor: fullname: I Bosone – volume: 462 start-page: 739 year: 2009 ident: 596_CR23 publication-title: Nature doi: 10.1038/nature08617 contributor: fullname: L Dang – volume: 73 start-page: 1792 year: 2009 ident: 596_CR29 publication-title: Neurology doi: 10.1212/WNL.0b013e3181c34ace contributor: fullname: HJ Dubbink – volume-title: WHO classification of tumors of the central nervous systems year: 2007 ident: 596_CR37 contributor: fullname: DN Louis – volume: 15 start-page: 6002 year: 2009 ident: 596_CR5 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-09-0715 contributor: fullname: S Nobusawa – volume: 6 start-page: 219 year: 2009 ident: 596_CR38 publication-title: Cancer Genomics Proteomics contributor: fullname: M Mellai – volume: 71 start-page: 37 year: 1985 ident: 596_CR20 publication-title: Hum Genet doi: 10.1007/BF00295665 contributor: fullname: K Narahara – volume: 116 start-page: 597 year: 2008 ident: 596_CR2 publication-title: Acta Neuropathol doi: 10.1007/s00401-008-0455-2 contributor: fullname: J Balss – volume: 75 start-page: 1560 year: 2010 ident: 596_CR30 publication-title: Neurology doi: 10.1212/WNL.0b013e3181f96282 contributor: fullname: C Houillier – volume: 19 start-page: 17 year: 2011 ident: 596_CR41 publication-title: Cancer Cell doi: 10.1016/j.ccr.2010.12.014 contributor: fullname: W Xu – volume: 120 start-page: 707 year: 2010 ident: 596_CR43 publication-title: Acta Neuropathol doi: 10.1007/s00401-010-0781-z contributor: fullname: C Hartmann – volume: 27 start-page: 5743 year: 2009 ident: 596_CR26 publication-title: J Clin Oncol doi: 10.1200/JCO.2009.23.0805 contributor: fullname: M Weller – volume: 360 start-page: 765 year: 2009 ident: 596_CR3 publication-title: N Engl J Med doi: 10.1056/NEJMoa0808710 contributor: fullname: H Yan – volume: 117 start-page: 653 year: 2009 ident: 596_CR19 publication-title: Acta Neuropathol doi: 10.1007/s00401-009-0528-x contributor: fullname: T Watanabe – ident: 596_CR28 doi: 10.1002/ijc.25448 – volume: 21 start-page: 74 year: 2011 ident: 596_CR17 publication-title: Brain Pathol doi: 10.1111/j.1750-3639.2010.00454.x contributor: fullname: A Deimling von – volume: 16 start-page: 387 year: 2010 ident: 596_CR14 publication-title: Trends Mol Med doi: 10.1016/j.molmed.2010.07.002 contributor: fullname: L Dang – volume: 18 start-page: 553 year: 2010 ident: 596_CR42 publication-title: Cancer Cell doi: 10.1016/j.ccr.2010.11.015 contributor: fullname: ME Figueroa – volume: 68 start-page: 1319 year: 2009 ident: 596_CR8 publication-title: J Neuropathol Exp Neurol doi: 10.1097/NEN.0b013e3181c391be contributor: fullname: C Horbinski – volume: 16 start-page: 1597 year: 2010 ident: 596_CR24 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-09-2902 contributor: fullname: MJ Bent van den – volume: 30 start-page: 7 year: 2009 ident: 596_CR11 publication-title: Hum Mutat doi: 10.1002/humu.20937 contributor: fullname: FE Bleeker – volume: 40 start-page: 1230 year: 2008 ident: 596_CR22 publication-title: Nat Genet doi: 10.1038/ng.223 contributor: fullname: DT Hartong – volume: 74 start-page: 1886 year: 2010 ident: 596_CR25 publication-title: Neurology doi: 10.1212/WNL.0b013e3181e1cf3a contributor: fullname: M Labussière – volume: 94 start-page: 297 year: 2009 ident: 596_CR16 publication-title: J Neurooncol doi: 10.1007/s11060-009-9855-y contributor: fullname: M Holdhoff – volume: 118 start-page: 401 year: 2009 ident: 596_CR32 publication-title: Acta Neuropathol doi: 10.1007/s00401-009-0550-z contributor: fullname: A Korshunov – volume: 321 start-page: 1807 year: 2008 ident: 596_CR1 publication-title: Science doi: 10.1126/science.1164382 contributor: fullname: DW Parsons – volume: 118 start-page: 469 year: 2009 ident: 596_CR4 publication-title: Acta Neuropathol doi: 10.1007/s00401-009-0561-9 contributor: fullname: C Hartmann – volume: 118 start-page: 599 year: 2009 ident: 596_CR31 publication-title: Acta Neuropathol doi: 10.1007/s00401-009-0595-z contributor: fullname: D Capper – volume-title: Brain tumor pathology: current diagnostic hotspots and pitfalls year: 2006 ident: 596_CR48 contributor: fullname: D Schiffer – volume: 174 start-page: 1149 year: 2009 ident: 596_CR7 publication-title: Am J Pathol doi: 10.2353/ajpath.2009.080958 contributor: fullname: T Watanabe |
SSID | ssj0004731 |
Score | 2.3323214 |
Snippet | A total of 343 brain tumors were studied for
IDH1
and
IDH2
mutations by direct sequencing and for protein expression by immunohistochemistry with mIDH1
R132H... A total of 343 brain tumors were studied for IDH1 and IDH2 mutations by direct sequencing and for protein expression by immunohistochemistry with mIDH1(R132H)... A total of 343 brain tumors were studied for IDH1 and IDH2 mutations by direct sequencing and for protein expression by immunohistochemistry with mIDH1^sup... A total of 343 brain tumors were studied for IDH1 and IDH2 mutations by direct sequencing and for protein expression by immunohistochemistry with mIDH1... |
SourceID | proquest crossref pubmed springer |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 345 |
SubjectTerms | Adult Aged Aged, 80 and over Brain Neoplasms - genetics Brain Neoplasms - metabolism Brain Neoplasms - mortality Clinical Study – Patient Study DNA Methylation DNA Modification Methylases - genetics DNA Repair Enzymes - genetics DNA, Neoplasm - genetics Female Glioma - genetics Glioma - metabolism Glioma - mortality Humans Immunoenzyme Techniques Isocitrate Dehydrogenase - genetics Medicine Medicine & Public Health Middle Aged Mutation - genetics Neurology Oncology Polymerase Chain Reaction Prognosis Promoter Regions, Genetic - genetics Receptor, Epidermal Growth Factor - genetics Survival Rate Tumor Suppressor Protein p53 - genetics Tumor Suppressor Proteins - genetics Young Adult |
SummonAdditionalLinks | – databaseName: SpringerLink Journals (ICM) dbid: U2A link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3dS8MwED_mBPFF_LZOJQ8-qRWbpFn7ONQxhfnkYPhSkjSFIWtlbf9_L_1YET_At5amabhLLr9frncHcMm55D4NYjdUTLlcD2NXIoFzQ-nJhAuqfG3PO6YvYjLjz3N_3gO6PrpI329bj2RlqLtYNyQv9h8qZL9-KFy2AZsWO9iZPKOjLhZy2NQgRAPgh3zeejJ_6uLrXvQNYH5zjlZ7zngXdhqwSEa1dvegZ9J92Jo27vADeHt6mHhEpjHBC0qWZe1Xz2_IwoZ9ZFUyYd2WdKsayk4dOVmkRBI7B01OsoQoWy6CFOUyW-WHMBs_vt5P3KZYgqu5CAo35kbigjWaKxZIicaDiZgNlZaJ5Vk0EHhzJ7RNiGe8WDMWU6oQ3iS46E2g2RH00yw1J0AEagmJX8gD7M0zXCXIGaV9V3tK-9SBq1Zs0UedEyPqsh9bGUco48jKOGIODFrBRs3yyCMkeV5ok4M5QNZPURbWWSFTk5V5FFrwhHD0ryZop32EQ4EDx7XG1sOhyAJZwHGo160Ku6__OtbTf7UewHZ1wFwFJp5Bv1iV5hwRSqEuqin5CY942zM priority: 102 providerName: Springer Nature |
Title | IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors |
URI | https://link.springer.com/article/10.1007/s11060-011-0596-3 https://www.ncbi.nlm.nih.gov/pubmed/21643842 https://www.proquest.com/docview/899195179/abstract/ https://search.proquest.com/docview/900631619 https://search.proquest.com/docview/911155548 |
Volume | 105 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT9wwEB7xkKpeKp7t8lj50FPB2sZ2EueEFlhYWoEQ6kpLL5HtOBIHEiDZ_89MNtkVQnDKy0lGM_Z4vhl7BuCnUkaFQmc8sdJy5eKMGwRwPDGByVUkbOjI33F9E40n6s80nK7AZbcXhpZVdjqxUdRZ6chHPkBcECSUT2pgLDkBXD04eXrmVD6KwqxtLY1VWA-wh1INB322XOuh4rYwIWqFMFHTLrzZ7KFDUERrsxBVh0nE5dsJ6p3V-S5i2kxEFxvwrbUg2XAu8k1Y8cUWfLluY-Tb8P_qfBwwU2QMTwR7nM2D7dUxe6C9IGWTYdh1dd6ahmYpo4o9FMww6pi-YmXOLNWQYPXssXypdmByMfp3NuZtBQXuVKRrnilvcBR7p6zUxqBGkVEmY-tMTuBL6AgvfkeOsuT5IHNSZkJYtHly1AReO7kLa0VZ-B_AIhQdosFEafxa4JXNEUgaetcF1oWiB786tqVP80QZ6TIlMvE4RR6nxONU9mC_Y2zajpkqXUi4B2zxFHlBEQxT-HJWpQlZVGijftYElXeINpLuwfe5xBbkCISGUisk9agT4fLvH9K69ymt-_C18TI3uxMPYK1-mflDNFNq24fVeBr3m47Yh_Xh5f3fER5PRze3d3h3IoavO0HnaA |
link.rule.ids | 315,786,790,12083,12250,21416,27957,27958,31754,31755,33301,33302,33779,33780,41116,41558,42185,42627,43345,43614,43840,52146,52269,74102,74371,74659 |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT8MwDLZgSMAF8WaMRw6cgAjapK8TQjw0HuO0SROXKElTiQMt0O3_Y3ftJjSxW6umrWUnjr_4BXAmpZaBH6c8McJwaaOUawRwPNGezmTom8DSeUfvLewO5PMwGNaxOWUdVtnoxEpRp4WlM_IrxAVeQvWkbr6-OTWNIudq3UFjGVakEJIi-qJhNEuLjOp2hKgLgkQOG6dmlTmHUIgishBLB0nIxd9tac7WnPOTVtvP4yZs1HYju50IeguWXL4Nq73aM74D70_3XY_pPGV44bPP8cTFXl6yD8oAKaq6wrbp7lYN1DPJlOwjZ5rRdHQlKzJmqHMEG40_i59yFwaPD_27Lq_7JnArw3jEU-k0rl1npRGx1qhHRJiKyFidEeTy4xBvrkNLtfGcl1ohUt83aOlkuP5dbMUetPIidwfAQhQYYsBExvg1z0mTIXzU9K71jA38Npw3bFNfk_IYalYImXiskMeKeKxEGzoNY1W9Uko1lWsb2PQp8oL8Fjp3xbhUCdlRaJkuGoIqO0DLKG7D_kRiU3J8BIQilkjqRSPC2d__pfVwIa2nsNbt917V69PbSwfWq3PmKj_xCFqjn7E7RkNlZE6q6fgLGg_h1Q |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT8MwDLZgSIgL4s0Yjxw4ARG0SV8nhIBpPMUBpIlLlKSpxIEW6Pb_sbt0E0Jwa9W0tezE8WfHNsChlFpGYZrzzAjDpU1yrhHA8UwHupBxaCJL_o6Hx3jwIm-H0dCXFKr9scpWJzaKOq8s-chPERcEGdWTOi38qYinq_75xyenBlIUaPXdNOZhATfJM2pmkAyTWYpk4lsTol6IMjlsA5xNFh3CIjqdhbg6ymIufm5Rv-zOXzHTZivqr8CytyHZxUToqzDnyjVYfPBR8nV4vbkaBEyXOcOLkL2PJ-H2-oS9UTZI1dQYtm2nt2agnkmpZm8l04ympqtZVTBDXSTYaPxefdUb8NK_fr4ccN9DgVsZpyOeS6dxHTsrjUi1Rp0i4lwkxuqC4FeYxnhzFluqk-eC3AqRh6FBq6dAXeBSKzahU1al2wYWo_AQD2Yyxa8FTpoCoaSmd21gbBR24ahlm_qYlMpQs6LIxGOFPFbEYyW60GsZq_yqqdVUxl1g06fIC4ph6NJV41plZFOhlfrfEFTfEVpJaRe2JhKbkhMiOBSpRFKPWxHO_v4nrTv_0noAizgT1f3N410PlhqXc5OquAud0dfY7aHNMjL7zWz8Bsg15gE |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=IDH1+and+IDH2+mutations%2C+immunohistochemistry+and+associations+in+a+series+of+brain+tumors&rft.jtitle=Journal+of+neuro-oncology&rft.au=Mellai%2C+Marta&rft.au=Piazzi%2C+Angela&rft.au=Caldera%2C+Valentina&rft.au=Monzeglio%2C+Oriana&rft.date=2011-11-01&rft.eissn=1573-7373&rft.volume=105&rft.issue=2&rft.spage=345&rft.epage=357&rft_id=info:doi/10.1007%2Fs11060-011-0596-3&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0167-594X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0167-594X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0167-594X&client=summon |